MRI MONITORING OF VIGABATRIN-INDUCED INTRAMYELINIC EDEMA IN DOGS

Citation
Kl. Weiss et al., MRI MONITORING OF VIGABATRIN-INDUCED INTRAMYELINIC EDEMA IN DOGS, Neurology, 44(10), 1994, pp. 1944-1949
Citations number
27
Categorie Soggetti
Clinical Neurology
Journal title
ISSN journal
00283878
Volume
44
Issue
10
Year of publication
1994
Pages
1944 - 1949
Database
ISI
SICI code
0028-3878(1994)44:10<1944:MMOVIE>2.0.ZU;2-2
Abstract
Chronic administration of vigabatrin (gamma-vinyl GABA) in dogs produc es reversible microvacuolation (intramyelinic edema) in discrete brain regions. Histologic changes are most notable in the columns of the fo rnix and regions of the hypothalamus, thalamus, optic tract, and hippo campus. In an attempt to image these changes in vivo, we performed hig h-field MRI on seven treated and four control dogs at baseline and aft er 15 weeks of dosing with vigabatrin (300 mg/kg/d). All dogs underwen t parallel electrophysiologic assessment to determine the effects of v igabatrin on afferent conduction. At 15 weeks, all treated dogs showed increased T-2. and decreased T-1-weighted signals, with changes from baseline most prominent in the columns of the fornix and to a lesser d egree in the surrounding hypothalamus and thalamus. MRIs performed on control dogs were unremarkable. We then perfused a random selection of four treated and two control dogs and imaged their brains ex vivo pri or to sectioning. Ex vivo imaging confirmed the in vivo findings and s trongly correlated with both electrophysiologic and subsequent histopa thologic findings. Imaging was repeated in the surviving dogs 5 and 12 weeks after discontinuation of dosing. Signal abnormalities in the tr eated dogs progressively diminished during recovery, paralleling the e lectrophysiologic and histopathologic results. These findings demonstr ate that MRI can detect signal changes anatomically congruent with vig abatrin-induced intramyelinic edema and suggest that MRI may provide a useful noninvasive tool for monitoring patients during clinical trial s.